Kathleen LaPorte
Managing Director, New Leaf Venture Partners
Ms. LaPorte, along with other members of the Sprout Group healthcare team, founded New Leaf Venture Partners (NLV Partners) in July 2005. NLV Partners invests primarily in firms focused on clinical-stage biopharmaceutical products, early-stage medical devices and molecular diagnostics. In addition, NLV Partners continues to manage the existing $800 million healthcare technology portfolio of Sprout Group. Ms. LaPorte joined the Sprout Group in 1993 and became a General Partner in 1994. Between 1987 and 1993, she was a principal at Asset Management Company, a venture capital firm focused on early-stage investments. Previously, she was a financial analyst with The First Boston Corporation. Ms. LaPorte currently serves as a member of the board of directors of ISTA Pharmaceuticals, Inc., a pharmaceutical company, Transcept Pharmaceuticals, Inc., a pharmaceutical company, and several privately held companies. Ms. LaPorte received a M.B.A. from Stanford University Graduate School of Business (Arjay Miller Scholar) and a B.S., summa cum laude, Phi Beta Kappa, from Yale University.